Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, gives an overview of the results of subgroup analyses from the CASTOR (NCT02136134) and POLLUX (NCT02076009) studies comparing daratumumab+bortezomib+dexamethasone vs bortezomib and dexamethasone and daratumumab+bortezomib+dexamethasone vs lenalidomide and dexamethasone respectively. Overall, the study showed that the benefit in progression-free survival (PFS) and overall survival (OS) was maintained across different subgroups including patients over 75 years old, patients with renal impairment, patients with high-risk cytogenetics, and patients previously exposed to lenalidomide, bortezomib or dexamethasone. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.